Trial record 1 of 1 for:
D0810C00020
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
This study is ongoing, but not recruiting participants.
Sponsor:
AstraZeneca
Collaborator:
British Columbia Cancer Agency
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00679783
First received: May 15, 2008
Last updated: March 28, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This is a Phase II, open label, non randomized correlative study of AZD2281 in patients with recurrent breast and ovarian cancer in both BRCA inherited mutation carriers and non-carriers to identify objective response rate and to assess for early markers of activity and to assess correlative markers that may provide helpful information for subsequent clinical trials. Approximately 110 patients from 7 centers in Canada will be enrolled into this study.
| Condition | Intervention | Phase |
|---|---|---|
|
Ovarian Carcinoma Breast Cancer |
Drug: AZD2281 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines [ Time Frame: Each patient with measurable disease at baseline was assessed for Objective Response from the sequence of RECIST scan data up to data cut-off, 26 March 2010. RECIST scans were performed every 8 weeks (+/- 2 weeks) from randomization. ] [ Designated as safety issue: No ]Percentage of participants with confirmed best RECIST response of complete response (CR) or partial response (PR). Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.
Secondary Outcome Measures:
- Disease Control Rate (DCR) [ Time Frame: 16 Weeks ] [ Designated as safety issue: No ]Percentage of participants with confirmed best Response Evaluation Criteria In Solid Tumours (RECIST) response of complete response (CR), partial response (PR) orStable Disease (SD)
- Duration of Response [ Time Frame: RECIST tumour assessments carried out every 8 weeks from randomization (+/- 2 weeks) until data cut-off on 26 March 2010. ] [ Designated as safety issue: No ]Duration of response is measured from the time the measurement criteria for CR or PR are met (whichever is first recorded) until the patient progresses (per RECIST criteria). If patient did not progress, they are censored at their last objective tumour assessment date.
- Best Percentage Change From Baseline in Tumour Size [ Time Frame: Each patient with measurable disease at baseline was assessed for best percentage change in tumour size from the sequence of RECIST scan data up to data cut-off, 26 March 2010. RECIST scans were performed every 8 weeks (+/- 2 weeks) from randomization. ] [ Designated as safety issue: No ]The best percentage change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).
- CA-125 Levels (Ovarian Cancer Patients Only) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]A response according to CA-125 has occurred if there is at least a 50% reduction in CA-125 levels from a pre-treatment sample.
- Progression Free Survival (PFS) [ Time Frame: RECIST tumour assessments carried out every 8 weeks from randomization (+/- 2 weeks) until data cut-off on 26 March 2010. ] [ Designated as safety issue: No ]PFS is defined as the time from first dose to the earlier date of radiologic progression (as per Response Evaluation Criteria In Solid Tumours (RECIST) criteria or death by any cause in the absence of objective progression.
| Enrollment: | 91 |
| Study Start Date: | July 2008 |
| Estimated Study Completion Date: | December 2012 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
AZD2281, PARP inhibitor
|
Drug: AZD2281
PARP inhibitor
Other Name: Olaparib
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically confirmed high grade serous and/or undifferentiated carcinoma of ovary, fallopian tube or peritoneum
- Oestrogen, progesterone and HER2 negative advanced adenocarcinoma of the breast
- Known BRCA positive breast cancer or ovarian cancer, that is not high grade serous or undifferentiated tubo-ovarian carcinoma.
- Performance status of no more than 2.
Exclusion Criteria:
- Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry
- Major surgery with 4 weeks of entering the study and must have recovered from effects of any major surgery .
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00679783
Locations
| Canada, Alberta | |
| Research Site | |
| Edmonton, Alberta, Canada | |
| Canada, British Columbia | |
| Research Site | |
| Vancouver, British Columbia, Canada | |
| Canada, Ontario | |
| Research Site | |
| Hamilton, Ontario, Canada | |
| Research Site | |
| Toronto, Ontario, Canada | |
| Canada, Quebec | |
| Research Site | |
| Montreal, Quebec, Canada | |
Sponsors and Collaborators
AstraZeneca
British Columbia Cancer Agency
Investigators
| Study Chair: | Karen Gelmon, MD | British Columbia Cancer Agency |
| Study Director: | Jane Robertson, BSc, MBCHB, MD | AstraZeneca |
More Information
No publications provided by AstraZeneca
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT00679783 History of Changes |
| Other Study ID Numbers: | D0810C00020 |
| Study First Received: | May 15, 2008 |
| Results First Received: | July 19, 2011 |
| Last Updated: | March 28, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by AstraZeneca:
|
Breast cancer Ovarian cancer BRCA Triple negative |
Poly(ADP ribose) polymerases Known BRCA or Recurrent High Grade Serious/ Undifferentiated Tubo- Ovarian Carcinoma Known BRCA or Triple Negative Breast Cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Carcinoma Ovarian Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Neoplasms by Histologic Type |
Endocrine Gland Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders |
ClinicalTrials.gov processed this record on May 19, 2013